Skip to main content

Renowned Surgeon Dr. Bartley Griffith Named Vice Chair for Innovation in UM School of Medicine’s Department of Surgery

January 31, 2024

Bartley P. Griffith, MDNew Position Will Highlight Importance of Achieving Breakthroughs in the Field and Mentoring Growth of Surgical Innovation in Department

University of Maryland School of Medicine (UMSOM) Department of Surgery Chair Christine Lau, MD, MBA, along with UMSOM Dean Mark T. Gladwin, MD,  announced today the appointment of Bartley P. Griffith, MD, as the Department of Surgery’s first Vice Chair for Innovation. In this role, Dr. Griffith will nurture a culture of innovation, entrepreneurship, and collaboration in the Department, and expand the integration of related sciences into surgical practice. The appointment is effective on February 1.

Christine Lau, MD, MBA“Dr. Griffith is one of the most nationally and internationally known heart surgeons in the world. There is no area of heart surgery that he has not impacted,” said Dr. Lau, who is the Dr. Robert W. Buxton Professor and Chair of the Department of Surgery at UMSOM and Surgeon-in-Chief at the University of Maryland Medical Center. “We look forward to the additional impact he will now have in supporting the development of translatable technological innovations in the department and collaborating with colleagues within the School of Medicine and the University of Maryland Medical System at large.”

Transplant Pioneer

Dr, Griffith in Xenotransplant surgeryDr. Griffith is a pioneer in heart and lung transplantation and education. In January 2022, he became the first surgeon in the world to implant a genetically modified pig heart into a living patient in partnership with Muhammad Mohiuddin, MD, Professor of Surgery at UMSOM. The 57-year-old patient lived for two months, and the surgery was hailed as a breakthrough. A second patient received a pig heart in October 2023 and lived for several weeks. Dr. Griffith serves as the Clinical Director of the Cardiac Xenotransplantation Program at UMSOM, and Dr. Mohiuddin as the program’s Program/Scientific Director.

Dr. Griffith has had significant funding throughout his career and currently has over $40 million in extramural funding. He is also an accomplished entrepreneur holding 10 issued patents and has established three companies. In the 1980s, he was the first to develop a method of auto-perfusion of a donor heart-lung bloc to enable procurement and transport of these organs at a distance far from the recipient. In 1985, he introduced a total artificial heart as a short-term bridge for morbidly ill patients awaiting a human heart transplant. In 1990, he was the first to receive permission from the U.S. Food and Drug Administration to discharge patients on implanted ventricular assist devices (VADs) from the hospital. He founded the $13 million McGowan Center for Artificial Organs in 1994. In collaboration with engineers, he developed  and was among the first to implant the novel and benchmarking rotary Heartmate II VAD, now implanted in more than 15,000 patients.

Entrepreneurial Leader

Mark T. Gladwin, MDIn 1998, he began a successful, decades-long NHLBI-supported program to develop an artificial lung. Key to this development were his partnerships forged with bioengineers and an emphasis on the use of computer-aided design to maximize biocompatibility of flow paths. The device was licensed to Breethe, a University of Maryland spinoff company, which was later sold to Abiomed. The FDA approved the device, and it is now available to patients.

“Bart Griffith is an entrepreneurial leader who will exponentially increase the number of novel ideas generated throughout the Department of Surgery that will translate into successful grant proposals and business ventures,” said Dr. Gladwin, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM, and Vice President for Medical Affairs at University of Maryland, Baltimore. “As Baltimore and the Maryland Biotech Corridor continues its strong momentum, there is no one better suited for this new position to foster a culture of innovation and to mentor the next generation of surgeon-scientists.”

Dr. Griffith will serve as a vital mentor and educator to medical students, surgeons in training, and young surgeons starting in their careers who are looking to capitalize on novel techniques and advances in their field.

Bert W. O’Malley, MD“Throughout his extraordinary career, Dr. Griffith has pushed the boundaries of medicine to advance solutions to some of the most complex medical challenges,” said Bert W. O'Malley, MD, President and CEO of the University of Maryland Medical Center. “I welcome this opportunity to better leverage his unique insight and pioneering spirit to further accelerate UMMC’s and the School of Medicine’s joint commitment to discovery and clinical translation.”

Added Dr. Griffith who is the Thomas E. and Alice Marie Hales Distinguished Professor of Transplant Surgery at UMSOM: “I am honored to accept this new position and look forward to complementing my patient and surgical care with this new emphasis. Patients in need have always been the inspiration for new operative therapies and device. I wish to enlist my colleagues to pursue ideas that excite them with the goal of saving more patients’ lives.”

Award-Winning Surgeon

Dr. Griffith has received multiple honors and awards throughout his career. Internationally, he was an honorary professor at Harbin Medical University in Harbin, China, and was inducted into the Royal College of Surgeons in Edinburgh, Scotland, United Kingdom. At the UMSOM, he received the Regents Faculty Award for Research, Scholarship, and Creative Activity, the Founders Week Faculty Research Lecturer of the Year, and the R. Adams Cowley Shock Trauma Hero Award. During the past four years, honors for the National Society include the Lillehei Lecture at the Society of Thoracic Surgeons Annual Meeting, Innovation Award in Mechanical Circulatory Support at the American Association for Thoracic Surgery Symposium; New Frontiers in Transplantation at the Society of Thoracic Surgeons Annual Meeting; William W.L. Glenn Lecture at the American Heart Scientific Sessions, Bakken Award at the Society of Thoracic Surgeons Annual Meeting; and John Gibbon, Jr., Lecture at the American College of Surgeons Clinical Congress. 

Bradley Taylor, MD, MPH“Historic accomplishments like the cardiac xenotransplant would not have been possible without the world-class surgical skills that Dr. Griffith brought into the operating room,” said Bradley Taylor, MD, MPH, the Dr. Joseph S. and Irene P. McLaughlin Professor of Cardio-Thoracic Surgery. He has demonstrated time and again his commitment to innovation and in mentoring the next generation of surgeons.”

Dr. Griffith received his medical degree from Jefferson Medical College in 1974. He completed his internship, General & Cardiothoracic Surgery residency, and fellowship, all from the University of Pittsburgh School of Medicine in 1981. He subsequently joined the University of Pittsburgh School of Medicine faculty and moved up the ranks, serving as Vice Chair of the Department of Surgery from 1996 to 2001. In 2001, Dr. Griffith joined the University of Maryland School of Medicine faculty as Professor of Surgery with Tenure and served as the Chief of the Division of Cardiac Surgery until 2012. In 2008, Dr. Griffith received the Thomas E. and Alice Marie Hales Distinguished Professor. He was the Director of Cardiopulmonary Transplantation from 2001-2013 and 2017-2020 and the Cardiothoracic Residency Program from 2001-2019 at the UMSOM. 

Dr. Griffith is a highly accomplished scholar and lecturer with an impressive list of credentials. He has authored more than 850 peer-reviewed articles, a book, and more than 80 book chapters. He has presented at numerous local, regional, national, and international meetings, including the "Celebrating a Medical Breakthrough" event at Mass General Brigham in Boston, MA.

A member of various major national societies and medical boards, he has served on multiple committees in leadership roles, including editorial boards and consultant roles for eleven companies. Among his proudest accomplishments, he also founded the Family House for transplant patients.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $500 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit

About the University of Maryland Medical Center

The University of Maryland Medical Center (UMMC) is comprised of two hospital campuses in Baltimore: the 800-bed flagship institution of the 11-hospital University of Maryland Medical System (UMMS) and the 200-bed UMMC Midtown Campus. Both campuses are academic medical centers for training physicians and health professionals and for pursuing research and innovation to improve health. UMMC's downtown campus is a national and regional referral center for trauma, cancer care, neurosciences, advanced cardiovascular care, and women's and children's health, and has one of the largest solid organ transplant programs in the country. All physicians on staff at the downtown campus are clinical faculty physicians of the University of Maryland School of Medicine. The UMMC Midtown Campus medical staff is predominantly faculty physicians specializing in a wide spectrum of medical and surgical subspecialties, primary care for adults and children and behavioral health. UMMC Midtown has been a teaching hospital for 140 years and is located one mile away from the downtown campus. For more information, visit


Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Tuesday, October 31, 2023

    In Memoriam: Lawrence Faucette

    It is with great sadness that we announce the passing of Lawrence Faucette, the 58-year-old patient with terminal heart disease who received the world’s second genetically-modified pig heart transplant. Mr. Faucette received the transplant on September 20 and lived for nearly six weeks following the surgery.

    Friday, September 22, 2023

    UM Medicine Faculty-Scientists and Clinicians Perform Second Historic Transplant of Pig Heart into Patient with End-Stage Cardiovascular Disease

    A 58-year-old patient with terminal heart disease became the second patient in the world to receive a historic transplant of a genetically-modified pig heart on September 20. He is recovering and communicating with his loved ones. This is only the second time in the world that a genetically modified pig heart has been transplanted into a living patient. Both historic surgeries were performed by University of Maryland School of Medicine (UMSOM) faculty at the University of Maryland Medical Center (UMMC).

    Friday, June 30, 2023

    Lessons Learned from World’s First Successful Transplant of Genetically-Modified Pig Heart into Human Patient

    A new study published today in the Lancet has revealed the most extensive analysis to date on what led to the eventual heart failure in the world's first successful transplant of a genetically-modified pig heart into a human patient. This groundbreaking procedure was conducted by University of Maryland School of Medicine (UMSOM) physician-scientists back in January 2022 and marked an important milestone for medical science.

    Friday, December 16, 2022

    UM School of Medicine Surgeon-Scientist Named One of Nature’s 10 People Who Helped Shape the Science Stories of 2022

    The world-renowned journal Nature, named Muhammad Mohiuddin, MD, DSc, Program and Scientific Director of the Cardiac Xenotransplantation Program at the University of Maryland School of Medicine (UMSOM), on its annual list of 10 people who helped shaped science in 2022. His pivotal work over the past three decades transplanting genetically-modified pig hearts into non-human primates led to the historic xenotransplant of a pig heart into a human patient this past January. The surgery was led by Bartley Griffith, MD, the Thomas E. and Alice Marie Hales Distinguished Professor of Transplant Surgery and Clinical Director of the Cardiac Xenotransplantation Program, who was also recognized by Nature for his ground-breaking efforts to move the field of transplantation into a new era.

    Monday, November 14, 2022

    Unexpected Electrical Changes Seen in First Successful Transplant of Genetically-Modified Pig Heart

    Ten months after transplanting the first genetically-modified pig heart into a human patient, University of Maryland School of Medicine (UMSOM) researchers continue to report on new findings from the landmark transplant. Their latest study demonstrates for the first time that unexpected electrical changes occurred in the pig heart transplanted into the patient David Bennett. The findings were presented at the American Heart Association (AHA) meeting this past weekend.

    Wednesday, June 22, 2022

    University of Maryland School of Medicine Faculty Scientists and Clinicians Publish Findings of World’s First Successful Transplant of Genetically Modified Pig Heart into Human Patient

    Six months ago, University of Maryland School of Medicine surgeon-scientists successfully implanted a genetically modified pig heart into a 57 year-old patient with terminal heart disease in a first-of-its-kind surgery. It was considered an early success because the patient lived for two months with a strong functioning heart showing no obvious signs of rejection, according to a new paper published today in the New England Journal of Medicine.

    Wednesday, March 09, 2022

    IN MEMORIAM: David Bennett, Sr.

    David Bennett, the 57 year old patient with terminal heart disease who made history as the first person to receive a genetically modified pig’s heart, passed away yesterday on March 8. Mr. Bennett received the transplant on January 7 and lived for two months following the surgery. His condition began deteriorating several days ago. After it became clear that he would not recover, he was given compassionate palliative care. He was able to communicate with his family during his final hours.